## Note
nid: 1503531036300
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_2::Cheesy_Dorian_(M3), #AK_Step2_v11::!Shelf::#Cards_AnKing_Skipped, #AK_Step2_v11::!Shelf::IM::no_dupes, #AK_Step2_v11::!Shelf::IM::no_dupes::only_step2, #AK_Step2_v11::#OME_banner, #AK_Step2_v11::#Resources_by_rotation::IM::uw::heme/onc::heme/onc_dorian, #AK_Step2_v11::#Resources_by_rotation::IM::uw::heme/onc::heme/onc_zanki, #AK_Step2_v11::#Subjects::Immunology_&_Pathology::02_Immunology::Hypersensitivity::Transfusion_Reaction, #AK_Step2_v11::#Subjects::Immunology_&_Pathology::02_Immunology::Hypersensitivity::Transfusion_Reaction::Febrile_Nonhemolytic_Transfusion_Reaction, #AK_Step2_v11::Original_decks::Dorian::im::uw::heme/onc, #AK_Step2_v11::Original_decks::Zanki_Step_2::IM::HemeOnc
markdown: false

### Text
What is the recommended <i>RBC pre-treatment</i> for a patient who
will receive a transfusion of pRBCs and has a history of <b>febrile
<u>non</u>-hemolytic transfusion reaction</b>?
<div>
  {{c1::Leukoreduction}}
</div>

### Extra
<i>removes the leukocytes that are the source of cytokines; also
useful for reducing risk of CMV transmission and HLA
alloimmunization</i>
<div>
  <div>
    <i><img src="rbc%20tx.png"></i>
  </div>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_4.png"></a>
</div>

### Additional Resources


### One by one

